Georgeann Pribek Colantone, age 64, passed away peacefully on Thursday, August 28, 2025, after a five year illness with ...
ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102 ...
TipRanks on MSN
Arvinas Announces Positive Phase 1 Trial Results
Arvinas Holding Company ( ($ARVN) ) has issued an update. On October 5, 2025, Arvinas, Inc. announced positive Phase 1 clinical trial results for ...
Va., has reintroduced legislation by former Rep. Jennifer Wexton, D-Va., that would require regulators to issue new guidance ...
Arvinas has announced positive biomarker, pharmacokinetic and pharmacodynamic data from two Phase I studies assessing ARV-102 ...
TipRanks on MSN
Arvinas price target raised to $16 from $14 at Piper Sandler
Piper Sandler raised the firm’s price target on Arvinas (ARVN) to $16 from $14 and keeps an Overweight rating on the shares. ARV-102 is an oral, ...
Milton Keynes Citizen on MSN
Radio 4 Appeal highlights urgent need for research into rare brain disease
This October, Milton Keynes based charity, the PSP Association, will be broadcasting a heartfelt appeal to fund life-changing ...
News-Medical.Net on MSN
Discovery of unique brain cells sheds light on progressive multiple sclerosis
Scientists have identified an unusual type of brain cell that may play a vital role in progressive multiple sclerosis (MS), ...
Sirio Persichetti can't speak and can't feed himself but the seven-year-old has taken the social media world by storm with his daily antics, proving that a disability is no barrier to inspiring others ...
Introduction Only symptomatic treatments are available for patients with Parkinson’s disease (PD), the second most common chronic neurodegenerative disease worldwide, and it is therefore imperative to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback